



## **7<sup>TH</sup> INTERNATIONAL EFR CONGRESS**

# **SURGICAL CONGRESS: MULTIDISCIPLINARY TREATMENT OF COLORECTAL CANCER**

**28.04. – 30.04.2011**

**Vienna General Hospital, Austria**

**[www.effcancer.org](http://www.effcancer.org)**

**PROGRAMME**

**ERBITUX®**  
CETUXIMAB



Merck Serono Oncology | *Combination is key™*

**Merck Serono**

Merck Serono is a  
division of Merck



# TABLE OF CONTENT

<b>1. Welcome Letters</b>	<b>4</b>
1.1. Federal President of the Republic of Austria	4
1.2. President of the EFR	5
<b>2. Programme overview</b>	<b>6</b>
<b>3. Scientific programme</b>	<b>7</b>
<b>4. Chairs, moderators &amp; speakers</b>	<b>14</b>
<b>5. Posters</b>	<b>19</b>
5.1. Poster viewing	19
5.2. Oral presentations & poster prize	19
5.3. Publication of poster abstracts	19
5.4. Poster authors	22
<b>6. Social programme</b>	<b>27</b>
6.1. Welcome reception	27
6.2. Gala dinner	28
<b>7. General information</b>	<b>29</b>
7.1. Accreditation	29
7.1.1. ECMEC credits	29
7.1.2. DFP points	29
7.2. Certificate of attendance	29
7.3. Congress organisation	30
7.4. Congress venue	30
7.5. Hotel accommodation	31
7.6. Language	32
7.7. Registration	32
7.7.1. Registration desk & EFR congress office	32
7.7.2. Registration fees	32
7.8. Speaker information	33
7.9. Sponsors & exhibitors	34
7.9.1. Main sponsors	34
7.9.2. Further sponsors & exhibitors	35
7.10. Imprint	36



## PREFACE

by the Federal President of the Republic of Austria, Dr. Heinz Fischer

The EFR Congress is to promote scientific progress in the field of colorectal cancer. In this function this congress will set important new signs in a time of scientific progress. Even though the recent results in the field of cancer research and cancer treatment have been remarkable, there is still much work left, which can be achieved in the best way if people pursue a common goal together. By paraphrasing Sir Karl Popper "I may be wrong and you may be right, but together we can try to move a little bit closer to the truth.", I may wish all visitors and participants an interesting and successful congress.



A handwritten signature in black ink that reads "Heinz Fischer". The signature is written in a cursive, flowing style.

Dr. Heinz Fischer  
Federal President of the Republic of Austria



## OPENING ADDRESS

by the EFR President, Béla Teleky




The World Health Organisation has set itself ambitious targets. In the future, one third of all cancer cases worldwide shall be avoided by adequate prevention and changing goals in life. Another third is to be prevented by early detection and the remaining cases by progress in medical research. It is with definite pride that I can say that this Congress will focus on a type of cancer for which both prevention and better understanding of tumor-biological processes is of particular importance – colorectal cancer, the second most common cancer disease worldwide.

For this 7th International Symposium we have managed to invite and attract opinion leaders from several continents to give the attendants the opportunity to gather new scientific experience and know-how on treatment-related methods for improving prognosis and chances of cure and healing for patients. The program of this Congress will focus on improved diagnostic options, prognostic factors and surgical techniques, but also on the progress made in the field of state-of-the-art radio- and chemotherapy. The presentations have been organized to allow sufficient time for interdisciplinary discussions.

Many of the topics the speakers will discuss have been selected with the goal in mind to present controversial statements for which a common consensus is to be sought in the ensuing discussions. In addition, poster sessions will give opportunity for young scientists and researchers to present the focus of their research work and the related therapeutic results with the best poster being awarded a special prize. As president of this scientific meeting I consider it as my task to provide the participants with an opportunity to extend their scientific horizon, familiarize themselves with new ideas and learn about critical interpretations of study results.

Focal Congresses like this one will give the attendants the chance to obtain a global understanding if colorectal cancer – from molecular biology to individual treatment concepts and approaches – in concise but yet comprehensive form.

The social program of the 7th EFR Congress has been designed to provide the participants with an impression of the major artistic feats of the city of Vienna. In the historical Belvedere, you will be given the chance of being intimately close to pictures and paintings of Klimt, Schiele and Kokoschka. Enjoying blissful music at the Coat of Arms Hall of the Vienna City Hall you will have the opportunity of getting to know new people, build new friendships and meet old acquaintances again.



Béla Teleky, MD, FRCS  
President of the EFR

## PROGRAMME OVERVIEW

THURSDAY, APRIL 28	
13:00 – 13:30	Opening
13:30 – 15:00	Session I
15:00 – 15:30	Coffee break & exhibition
15:30 – 17:00	Session II
17:00 – 18:00	Roundtable & case study discussion – Merck Serono (limited attendants)
19:00	Welcome reception at the Upper Belvedere (Bus transfer from the congress at 18:30)



FRIDAY, APRIL 29	
08:30 – 10:00	Session III
10:00 – 10:30	Coffee break & exhibition
10:30 – 12:00	Session IV
12:00 – 13:00	Lunch & poster viewing & exhibition
13:00 – 14:30	Session V
14:30 – 15:00	Coffee break & exhibition
15:00 – 16:30	Session VI
16:30 – 17:00	Coffee break & exhibition
17:00 – 18:00	Session VII
19:30	Gala dinner at the Vienna City Hall



SATURDAY, APRIL 30	
08:30 – 10:00	Session VIII
10:00 – 10:30	Coffee break & exhibition
10:30 – 12:00	Session IX
12:00 – 12:30	Poster Award
12:30	Closing Remarks



# SCIENTIFIC PROGRAMME

**THURSDAY, APRIL 28**

## 13:00 – 13:30 Opening

Schütz W. – Rector of the Medical University of Vienna

Zielinski C. – Coordinator of the CCC - Comprehensive Cancer Center

Krepler R. – Director of the Vienna General Hospital

Doris Bures – Minister for transport, innovation and technology

## 13:30 – 15:00 Session I

Moderation: Jakesz R. (A)

Chairs: Korcek J. (SK), Wrba F. (A)

13:30 – 13:50 Nicholls J. (GB)

Evolution and revolution in colorectal cancer

13:50 – 14:05 Andrea Maier (A)

EUS and MRI in the diagnosis of rectal cancer

14:05 – 14:20 Mariana Berho (US)

The role of molecular markers in the treatment of colorectal cancer

14:20 – 14:40 Iris Nagtegaal (NL)

Rectal cancer: what to expect from your pathologist?

14:40 – 15:00 Discussion

15:00 – 15:30 Coffee break & exhibition  
sponsored by Nycomed



**15:30 – 17:00 Session II**

Moderation: Lechner P. (A)

Chairs: Trauner M. (A), Glaser K. (A)

- 15:30 – 15:45 **Marshall J. (US)**  
Lessons learned from the successes in colon cancer
- 15:45 – 16:00 **Moran B. (GB)**  
Concept of TME for rectal cancer
- 16:00 – 16:15 **Rullier E. (F)**  
Laparoscopic TME for rectal cancer
- 16:15 – 16:35 **Adam R. (F)**  
Onco-surgical management of colorectal liver metastases
- 16:35 – 17:00 **Discussion**

**17:00 – 18:00 Roundtable & case study discussion –  
Merck Serono (limited attendants)****MERCK**

- 18:30 Bus transfer from Vienna General Hospital to Upper Belvedere
- 19:00 Welcome reception at the Upper Belvedere  
(Guided tour: Klimt, Schiele, Kokoschka)

**FRIDAY, APRIL 29****08:30 – 10:00 Session III**

Moderation: Schiedeck T. (D)

Chairs: Pfeifer J. (A), Pravosudov I. (RUS)

- 08:30 – 08:50 **Wexner S. (US)**  
Current status of laparoscopy for colorectal carcinoma



- 08:50 – 09:05 **Paty P. (US)**  
Anterior Resection Syndrome: new insights into an old problem
- 09:05 – 09:20 **Herbst F. (A)**  
Experience with the ColonRing™ in rectal reconstruction
- 09:20 – 09:35 **Krivokapic Z. (SRB)**  
Multivisceral resection of rectal cancer
- 09:35 – 09:45 **Jano Z. (H)**  
Results of mesh implantations at the time of Miles operation to prevent parastomal hernia
- 09:45 – 10:00 **Discussion**
- 10:00 – 10:30 **Coffee break & exhibition**

#### 10:30 – 12:00 Session IV

Moderation: Adamina M. (CH)

Chairs: Shelygin Y. (RUS), Hauser H. (A)

- 10:30 – 10:50 **Hohenberger W. (D)**  
Complete Mesocolic Excision – a way to standardize colon cancer surgery
- 10:50 – 11:05 **Pahlman L. (SWE)**  
5 x 5 Gy in rectal cancer treatment – why not more often?
- 11:05 – 11:20 **Romano G. (I)**  
Short term RT with long interval to surgery does impact on prognosis of rectal cancer
- 11:20 – 11:35 **Rullier E. (F)**  
Local Excision vs. TME for downstaged rectal cancer after radiochemotherapy: the GRECCAR 2 Trial
- 11:35 – 12:00 **Discussion**
- 12:00 – 13:00 **Lunch & poster viewing & exhibition**



**13:00 – 14:30 Session V**

Moderation: Steininger R. (A)

Chairs: Schindl M. (A), Längle F. (A)

- 13:00 – 13:10 **Skricka T. (CZ)**  
Some fragments from the history of rectal cancer treatment
- 13:10 – 13:25 **Gnant M. (A)**  
Success and challenges of an academic research network in Austria – the ABCSG story
- 13:25 – 13:40 **Lygidakis N. (GR)**  
New insights in pathogenesis management of metastatic liver disease of colorectal origin
- 13:40 – 13:55 **Grünberger T. (A)**  
Defining resectability and the value of targeted agents in the neoadjuvant treatment of colorectal liver metastases
- 13:55 – 14:05 **Silberhumer G. (A), Fong Y. (US)**  
Simultaneous resection of liver metastases in rectal cancer
- 14:05 – 14:30 **Discussion**
- 14:30 – 15:00 **Coffee break & exhibition**  
sponsored by Österreichische Lotterien GmbH

**15:00 – 16:30 Session VI**

Moderation: Pötter R. (A)

Chairs: Karaitianos I. (GR), Szczepkowski M. (PL)

- 15:00 – 15:15 **Engel A. (NL)**  
The hostile pelvis
- 15:15 – 15:30 **Valentini V. (I)**  
When the radiation oncologist can help the surgeon in rectal cancer management
- 15:30 – 15:45 **Omejc M. (SLO)**  
Neoadjuvant treatment and perioperative outcome in rectal cancer

- 15:45 – 15:55 **Mammadli Z. (RUS)**  
Neoadjuvant thermoradiochemotherapy of rectal cancer – 5-years results
- 15:55 – 16:10 **Kartheuser A. (B)**  
TEM (Buess) for small rectal cancer treatment
- 16:10 – 16:30 **Discussion**
- 16:30 – 17:00 **Coffee break & exhibition**

### 17:00 – 18:00 Session VII

Chairs: Judith Karner-Hanusch (A), Bergmann M. (A)

- 17:00 – 17:15 **Daniela Kandioler (A)**  
The PART Trial – a phase III marker trial conducted by the EFR
- 17:15 – 17:30 **Oehler R. (A)**  
Proteomics analysis of plasma changes after the initial dose of Epirubicin/Docetaxel chemotherapy: characterization of biomarkers for prediction of the final response to therapy
- 17:30 – 17:45 **Christine Brostjan (A)**  
Systemic and local effects of Anti-VEGF Therapy
- 17:45 – 18:00 **Discussion**
- 19:30 **Gala Dinner at the Vienna City Hall  
(by invitation of the Mayor and Governor of Vienna)**

## SATURDAY, APRIL 30

### 08:30 – 10:00 Session VIII

- Moderation: Ludwig H. (A)  
Chairs: Gabriela Kornek (A), Damjanovich L. (H)
- 08:30 – 08:45 **Milicevic M. (SRB)**  
Repeated operation for CRC liver metastases
- 08:45 – 09:00 **Hoch J. (CZ)**  
Survival and quality of care for colorectal cancer – a 30-years experience of data collection in Czech Republic

- 09:00 – 09:15 **Punt C. (NL)**  
The optimal use of targeted agents in metastatic colorectal cancer
- 09:15 – 09:30 **Dziki A. (PL)**  
Lymph nodes as predictors of the outcome in rectal cancer
- 09:30 – 10:00 **Discussion**
- 10:00 – 10:30 **Coffee break & exhibition**

**10:30 – 12:00 Session IX**

Moderation: Zielinski C. (A)  
Chairs: Thaler J. (A), Nagy A. (H)

- 10:30 – 10:45 **Wexner S. (US)**  
Methods of reconstruction after total mesorectal excision
- 10:45 – 11:00 **van Cutsem E. (B)**  
Towards personalized therapy for metastatic colorectal cancer
- 11:00 – 11:15 **Paty P. (US)**  
Patterns of recurrence for resectable rectal cancer
- 11:15 – 11:30 **Scheithauer W. (A)**  
Adjuvant therapy for colon cancer in 2011
- 11:30 – 12:00 **Discussion**

**12:00 – 12:30 Poster Award**

Chair: Irene Kühner (A)

Oral presentation of 3 posters  
Poster prize – Ingeborg Hörhager Prize

**12:30 Closing Remarks**

Teleky B. (A)



Schneller von 0 auf 100,  
als Sie SLS AMG buchstabieren können.

Mehr über den neuen Supersportwagen auf [www.mercedes-benz.at/sls](http://www.mercedes-benz.at/sls)

Kraftstoffverbrauch 13,2 l/100 km, CO<sub>2</sub>-Emission 308 g/km



**AMG**

Mercedes-Benz

**Schranz Ges. m. b. H.** Autorisierter Mercedes-Benz Servicepartner und Verkaufsgent für Personenkraftwagen,  
7400 Oberwart, Grazer Straße 111, Tel. 0 33 52/38 0 27, Fax 0 33 52/38 0 27-19, e-mail: [schranz@mercedes.at](mailto:schranz@mercedes.at)

## CHAIRS, MODERATORS &amp; SPEAKERS

**ADAMINA M.** (CH), Canton Hospital of St. Gallen,  
michel.adamina@kssg.ch

**ADAM R.** (F), Hôpital Paul Brousse, Centre Hepto-Biliare, Paris,  
rene.adam@pbr.aphp.fr

**BERGMANN M.** (A), Medical University of Vienna,  
michael.bergmann@meduniwien.ac.at

**Mariana BERHO** (US), Cleveland Clinic Florida, berhom@ccf.org

**Christine BROSTJAN** (A), Medical University of Vienna,  
christine.brostjan@meduniwien.ac.at

**Doris BURES** (A), Minister for transport, innovation and technology

**DAMJANOVICH L.** (H), University of Debrecen, dami1960@dote.hu

**DZIKI A.** (PL), University of Lodz, adziki@wp.pl

**ENGEL A.** (NL), Zaans Medical Center, engel.a@zaansmc.nl

**FONG Y.** (US), Memorial Sloan-Kettering Cancer Center, New York,  
fongy@mskcc.org

**GLASER K.** (A), Wilhelminenspital, Vienna, karl.glaser@wienkav.at

**GNANT M.** (A), Medical University of Vienna, michael.gnant@meduniwien.ac.at

**GRÜNBERGER T.** (A), Medical University of Vienna,  
thomas.gruenberger@meduniwien.ac.at

**HAUSER H.** (A), Medical University of Graz, hubert.hauser@meduni-graz.at

**HERBST F.** (A), Barmherzige Brüder, Vienna, friedrich.herbst@bbwien.at

**HOCH J.** (CZ), Charles University Hospital, 2 Medical Faculty, Prague,  
jiri.hoch@fnmotol.cz

**HOHENBERGER W.** (D), Surgical Clinic Erlangen,  
werner.hohenberger@uk-erlangen.de

**JAKESZ R.** (A), Medical University of Vienna,  
raimund.jakesz@meduniwien.ac.at

**JANO Z.** (H), Veszprém Sebészeti Osztály, janogandalf@freemail.hu

**Daniela KANDIOLER** (A), Medical University of Vienna,  
daniela.kandioler@meduniwien.ac.at



**KARAITIANOS I.** (GR), Saint Savvas Hospital, Athens,  
igkaraitianos@hotmail.com

**Judith KARNER-HANUSCH** (A), Medical University of Vienna,  
judith.karner@meduniwien.ac.at

**KARTHEUSER A.** (B), University Hospital St. Luc,  
alex.kartheuser@uclouvain.be

**KORCEK J.** (SK), University Hospital Nitra, jozef.korcek@pobox.sk

**Gabriela KORNEK** (A), Medical University of Vienna,  
gabriela.kornek@meduniwien.ac.at

**KREPLER R.** (A), Director of Vienna General Hospital,  
reinhard.krepler@akhwien.at

**KRIVOKAPIC Z.** (SRB), University of Belgrade,  
scopy@beotel.net

**Irene KÜHRER** (A), Medical University of Vienna,  
irene.kuehrer@meduniwien.ac.at

**LÄNGLE F.** (A), General Hospital of Wr. Neustadt,  
friedrich.laengle@kh-wrn.ac.at

**LECHNER P.** (A), Regional Hospital of Tulln, p.lechner@aon.at

**LUDWIG H.** (A), Centre of Oncology and Haematology, Vienna,  
heinz.ludwig@wienkav.at

**LYGIDAKIS N.** (GR), International Association of Surgeons,  
Gastroenterologists and Oncologists, Athens, secretariat@iasg.org

**Andrea MAIER** (A), Medical University of Vienna,  
andrea.maier@meduniwien.ac.at

**MAMMADLI Z.** (RUS), Russian Oncologic Centre, Moscow,  
z.z.mamedli@gmail.com

**MARSHALL J.** (US), Georgetown University, marshalj@georgetown.edu

**MILICEVIC M.** (SRB), First Surgical Clinical Center Serbia, machak@sbb.rs

**MORAN B.** (GB), Basingstoke and North Hampshire Hospital,  
brendan.moran@bnhft.nhs.uk

**Iris NAGTEGAAL** (NL), Radboud University Nijmegen Medical Centre,  
i.nagtegaal@pathol.umcn.nl

**NAGY A.** (H), Veszprém Sebészeti Osztály, nagyarpad.md@gmail.com



**NICHOLLS J.** (GB), St. Mark's Hospital and Academic Institute of London,  
j.nicholls@thelondonclinic.co.uk

**OEHLER R.** (A), Medical University of Vienna, rudolf.oehler@meduniwien.ac.at

**OMEJC M.** (SLO), University of Ljubljana, mirko.omejc@kclj.si

**PAHLMAN L.** (SWE), University Hospital Uppsala,  
lars.pahlman@surgsci.uu.se

**PATY P.** (US), Memorial Sloan-Kettering Cancer Center, New York,  
patyp@mskcc.org

**PFEIFER J.** (A), Medical University of Graz, johann.pfeifer@medunigraz.at

**PÖTTER R.** (A), Medical University of Vienna,  
richard.poetter@meduniwien.ac.at

**PRAVOSUDOV I.** (RUS), N. N. Petrov Research Institute of Oncology,  
St. Petersburg, oncl1@rion.spb.ru

**PUNT C.** (NL), Radboud University Nijmegen Medical Centre,  
c.punt@onco.umcn.nl

**ROMANO G.** (I), Department of Chirurgica d'Urgenza, Naples,  
gromano53@katamail.com

**RULLIER E.** (F), Hôpital Saint André, Bordeaux, eric.rullier@chu-bordeaux.fr

**SCHEITHAUER W.** (A), Medical University of Vienna,  
werner.scheithauer@meduniwien.ac.at

**SCHIEDECK T.** (D), Clinical Centre of Ludwigsburg,  
thomas.schiedeck@kliniken-lb.de

**SCHINDL M.** (A), Medical University of Vienna,  
martin.schindl@meduniwien.ac.at

**SCHÜTZ W.** (A), Rector of the Medical University of Vienna,  
wolfgang.schuetz@meduniwien.ac.at

**SHELYGIN Y.** (RUS), State Research Centre of Coloproctology, Moscow,  
shelygin@yandex.ru

**SILBERHUMER G.** (A), Medical University of Vienna,  
gerd.silberhumer@meduniwien.ac.at

**SKRICKA T.** (CZ), Bakesova Nemocnice, Brno, t.skricka@gmail.com

**STEININGER R.** (A), Medical University of Vienna,  
rudolf.steiningr@meduniwien.ac.at



**SZCZEPKOWSKI M.** (PL), Bielanski Hospital, Warsaw,  
marek.szczepkowski@chello.pl

**TELEKY B.** (A), Medical University of Vienna,  
bela.teleky@meduniwien.ac.at

**THALER J.** (A), Klinikum Wels, josef.thaler@klinikum-wegr.at

**TRAUNER M.** (A), Medical University of Vienna,  
michael.trauner@meduniwien.ac.at

**VALENTINI V.** (I), Policlinico University "A. Gemelli", Rome,  
vvalentini@rm.unicatt.it

**VAN CUTSEM E.** (B), University Hospital Leuven,  
eric.vancutsem@uzleuven.be

**WEXNER S.** (US), Cleveland Clinic Florida, wexners@ccf.org

**WRBA F.** (A), Medical University of Vienna, fritz.wrba@meduniwien.ac.at

**ZIELINSKI C.** (A), Coordinator of the CCC - Comprehensive Cancer Center,  
Vienna, christoph.zielinski@meduniwien.ac.at



# Kompetenz beim Kolorektalkarzinom



**Angiogenese kontrollieren**

**AVASTIN®**  
bevacizumab  
Führend in der Angiogenesehemmung

**Leben verlängern**

First-Line  
**CRC**

**Entdecken Sie neue Wege in der Therapie des**

- advanced Kolonkarzinoms
- metastasierendes Kolorektalkarzinoms
- fortgeschrittenes Magenkarzinoms
- metastasierendes Mammakarzinoms

**Xeloda®**  
capecitabine  
Die Therapie zum Leben

**Avastin® 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung. Qualitative und quantitative Zusammensetzung:** Jeder Milliliter enthält 25 mg Bevacizumab. Jede Durchstechflasche enthält 100 mg Bevacizumab in 4 ml bzw. 400 mg in 16 ml, entsprechend 1,4 bis 16,5 mg/ml bei Verdünnung gemäß Empfehlung. Bevacizumab ist ein rekombinanter humanisierter monoklonaler Antikörper, der mittels DNA-Technologie aus Ovarialzellen des chinesischen Hamsters (CHO-Zellen) gewonnen wird. **Anwendungsgebiete:** Avastin (Bevacizumab) wird in Kombination mit einer Chemotherapie auf Fluoropyrimidin-Basis zur Behandlung von Patienten mit metastasiertem Kolon- oder Rektumkarzinom angewendet. Avastin wird in Kombination mit Capecitabine oder Docetaxel zur First-Line-Behandlung von Patienten mit metastasiertem Mammakarzinom angewendet. Zu weiteren Informationen wie auch zum HER2-Status siehe veröffentlichte Fachinformation Abschnitt 5.1 „Pharmakodynamische Eigenschaften“. Avastin wird zusätzlich zu einer Platin-haltigen Chemotherapie zur First-Line-Behandlung von Patienten mit inoperablem fortgeschrittenem, metastasiertem oder rezidivierendem nicht kleinzelligem Bronchialkarzinom, außer bei vorwiegender Plättchenplättchen-Histologie, angewendet. Avastin wird in Kombination mit Interferon alfa-2a zur First-Line-Behandlung von Patienten mit fortgeschrittenem und/oder metastasiertem Nierenzellkarzinom angewendet. **Gegenanzeigen:** Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile. Überempfindlichkeit gegen CHO-Zellprodukte oder andere rekombinante humane oder humanisierte Antikörper. Schwangerschaft (siehe veröffentlichte Fachinformation Abschnitt 4.6 „Fertilität, Schwangerschaft und Stillzeit“). Liste der sonstigen Bestandteile: -Trehalose 2 H<sub>2</sub>O, Natriumphosphat, Polysorbat 20, Wasser für Injektionszwecke. **Inhaber der Zulassung:** Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, Vereinigtes Königreich. **Verschreibungspflicht/Apothekenpflicht:** rezept- und apothekenpflichtig, wiederholte Abgabe verboten. **Pharmakotherapeutische Gruppe:** Monoklonale Antikörper; ATC-Code: L01X C07. **Besondere Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen sowie Informationen zu Schwangerschaft und Stillzeit und zu Nebenwirkungen sind der veröffentlichten Fachinformation zu entnehmen.**

**Xeloda® 150 mg Filmtabletten / Xeloda® 500 mg Filmtabletten. Qualitative und quantitative Zusammensetzung:** 150 mg / 500 mg Capecitabine. Sonstiger Bestandteil: 150 mg Filmtabletten: 15,6 mg wasserfreie Lactose. 500 mg Filmtabletten: 52 mg wasserfreie Lactose. **Anwendungsgebiete:** Xeloda ist zur adjuvanten Behandlung von Patienten nach Operation eines Kolonkarzinoms im Stadium III (Dukes Stadium C) indiziert (siehe veröffentlichte Fachinformation Abschnitt 5.1 „Pharmakodynamische Eigenschaften“). Xeloda ist zur Behandlung des metastasierten Kolorektalkarzinoms indiziert (siehe veröffentlichte Fachinformation Abschnitt 5.1 „Pharmakodynamische Eigenschaften“). Xeloda ist in Kombination mit einem Platin-haltigen Anwendungsschema als First-Line-Therapie des fortgeschrittenen Magenkarzinoms indiziert (siehe veröffentlichte Fachinformation Abschnitt 5.1 „Pharmakodynamische Eigenschaften“). Xeloda ist in Kombination mit Docetaxel (siehe veröffentlichte Fachinformation Abschnitt 5.1 „Pharmakodynamische Eigenschaften“) zur Behandlung von Patienten mit lokal fortgeschrittenem oder metastasiertem Mammakarzinom nach Versagen einer zytotoxischen Chemotherapie indiziert. Eine frühere Behandlung sollte ein Anthracyclin enthalten haben. Xeloda ist außerdem als Monotherapie zur Behandlung von Patienten mit lokal fortgeschrittenem oder metastasiertem Mammakarzinom indiziert, bei denen eine Therapie mit Taxanen und Anthracyclinen versagt hat oder eine weitere Anthracyclinbehandlung nicht angezeigt ist. **Gegenanzeigen:** Schwereviagrale und unerwartete Reaktionen bei Vorbehandlung mit Fluoropyrimidinen • Überempfindlichkeit gegen Capecitabine oder einen der sonstigen Bestandteile oder gegen Fluorouracil • bekannter Dihydropyrimidin-Dehydrogenase-Mangel (DPD) • Schwangerschaft und Stillzeit • schwere Leukopenie, Neutropenie oder Thrombozytopenie • schwere Beeinträchtigung der Leberfunktion • schwere Beeinträchtigung der Nierenfunktion (Kreatinin-Clearance < 30 ml/min • Behandlung mit Sorivudin oder dessen chemischen Verwandten, wie z.B. Brivudin (siehe veröffentlichte Fachinformation Abschnitt 4.5 „Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen“) • Wenn für eines der Arzneimittel der Kombinationstherapie Gegenanzeigen vorliegen, darf dieses Arzneimittel nicht angewendet werden. Liste der sonstigen Bestandteile: Tabletten: wasserfreie Lactose, Croscarmellose-Natrium, Hypromellose, mikrokristalline Cellulose, Magnesiumstearat. Filmüberzug: Hypromellose, Titanoxid (E171), Eisenoxidhydrat und Eisen(III)-oxid (E72), Talkum. **Inhaber der Zulassung:** Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, Vereinigtes Königreich. **Verschreibungspflicht/Apothekenpflicht:** rezept- und apothekenpflichtig, wiederholte Abgabe verboten. **Pharmakotherapeutische Gruppe:** Zytostatikum (Antimetabolit). ATC-Code: L01BC06. **Besondere Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen sowie Informationen zu Schwangerschaft und Stillzeit und zu Nebenwirkungen sind der veröffentlichten Fachinformation zu entnehmen.**

## POSTERS

### POSTER VIEWING

The posters will be exhibited next to the industry exhibition during the duration of the congress.

#### Mounting times

Thursday, April 28                      13:00 – 15:30

#### Poster exhibition hours

Thursday, April 28                      15:30 – 18:00

Friday, April 29                         08:30 – 18:00

Saturday, April 30                      08:30 – 12:00

#### Poster viewing

Friday, April 29                         12:00 – 13:00

#### Poster award session

Saturday, April 30                      12:00 – 12:30

### ORAL PRESENTATIONS & POSTER PRIZE

Out of 84 accepted abstracts, the best three papers have been chosen for oral presentation by a panel of referees. The abstracts will be presented on Saturday, 12:00 – 12:30, followed by the awarding of the Ingeborg Hörhager Prize for the best poster!

### PUBLICATION OF POSTER ABSTRACTS

All accepted abstracts are published as a supplement to European Surgery/ Acta Chirurgica Austriaca.

Registered participants receive their abstract book of the 7th International EFR Congress within their congress bags.

The production of the abstract book was fully sponsored by Amgen.



Please view the complete list of accepted posters online at [www.efrcancer.org](http://www.efrcancer.org)

Posters



Colon Resection Appendectomy  
Lap Bariatric Lap  
Nephrectomy  
Parotidectomy Live  
Tonsillectomy Axillary  
Breast augmentation Hysterectomy



**Of all the procedures in the OR,  
this may be the simplest.**

The new Ethicon-Endo-Surgery Generator combines advanced technology, multifunctionality and touch-screen simplicity in one sleek and easy-to-operate unit. No matter what the procedure or which EES device you plan to use, the EES Generator will be the only power source you'll need.

Johnson & Johnson MEDICAL Products GmbH  
**Ethicon Endo-Surgery** Österreich  
Vorgartenstr. 206B  
1020 WIEN

AD153, ©2010 Ethicon Endo-Surgery (Europe) GmbH.  
For complete product details see instructions for use.

ectomy Lymphadenectomy  
Dissection  
omy Prostatectomy  
colectomy  
Artery Harvesting  
Peripheral Vascular



- Universal connector and automatic instrument recognition
- Touch screen for fast and easy setup, operation, and on-screen diagnostics.
- HARMONIC® and ENSEAL® technology in one generator:

**Versatility and simplicity. That's positive energy.**



**Ethicon  
Endo-Surgery**

PART OF THE JOHNSON & JOHNSON FAMILY OF COMPANIES

## POSTER AUTHORS

**ALIEV F. SH.** (RUS), Tyumen State Medical Academy, egor\_@list.ru – **P36**

**ALIEV V. A.** (RUS), Russian Cancer Research Center, Moscow, afandi@inbox.ru – **P45, P46**

**ANITEI M-G.** (ROM), University of Medicine and Pharmacy “Gr.T.Popa” Iasi, dr.mgabriela@gmail.com – **P07, P08**

**ATROSHCHENKO A.** (RUS), Russian Cancer Research Center, Moscow, atroshchenko\_a@mail.ru – **P37, P38, P47**

**BANANZADEH A.** (IRA), Shiraz University of Medical Sciences, bananzadeh@gmail.com – **P48**

**BASHIRI H.** (IRA), Kermanshah University of Medical Sciences, hbashirimd@gmail.com – **P49**

**BENES M.** (CZ), IKEM “Institutu Klinické a Experimentální Medicíny”, Prague, mabx@medicon.cz – **P01, P02, P03**

**BERGMANN M.** (A), Medical University of Vienna, michael.bergmann@meduniwien.ac.at – **P72**

**BERTANI E.** (I), European Institute of Oncology – University of Milano, Emilio.bertani@ieo.it – **P09, P50**

**BUTA M.** (SER), Institute of Oncology and Radiology of Serbia, Belgrade, markobuta@yahoo.com – **P39**

**CADEDDU F.** (I), University Hospital Tor Vergata, Rome, fede.cadeddu@libero.it – **P10**

**CHAUDHRI S.** (UK) University Hospitals of Leicester, schaudhri@nhs.net – **P51**

**CHIAPPA A.** (I), European Institute of Oncology – University of Milano, Antonio.chiappa@ieo.it – **P11**

**DAMIANOV N.** (BUL), Military Medical Academy, Sofia, docdamianov@yahoo.com – **P12, P13, P14, P52, P53**

**DJURISIC I.** (SER), Institute for Oncology and Radiology in Belgrade, djurisic\_dr\_igor@yahoo.com – **P54**

**GANAPATHI S.** (UK), St. George’s Hospital Medical School, London, sganapat@sgul.ac.uk – **P73**



**GASHI Z.** (KOS), UCC – Gastrohepatologic Ward, Prishtina,  
drzaimgashi@hotmail.com – **P74**

**GHAHRAMANI L.** (IRA), Shiraz Medical University,  
leila\_ghahramani@yahoo.com – **P15, P55**

**GORDEYEV S.S.** (RUS), N.N. Blokhin Cancer Research Center,  
ss.netoncology@gmail.com – **P16**

**HOSSEINI S.V.** (IRA), Shiraz University of Medical Sciences,  
hoseiniv@sums.ac.ir – **P17**

**HULLA W.** (A), KFJ-Spital/SMZ-Süd, Vienna, wolfgang.hulla@wienkav.at –  
**P40**

**KALGANOV I.D.** (RUS), State Research Colorectal Center, Moscow,  
kalgan@mail.ru – **P75**

**KHAN K.** (UK), Betsi Cadwaladr University Health Board, North Wales,  
drkhurshid71@yahoo.com – **P04**

**KOLESNIK O.** (UKR), National Cancer Institute, Kiev, eakolesnik@ukr.net –  
**P41**

**KULUSHEV V. M.** (RUS), Russian Cancer Research Center, Moscow,  
kulushev@rambler.ru – **P18**

**LAE LEE K.** (KOR), Seoul National University College of Medicine,  
jasonlee600218@yahoo.co.kr – **P56**

**LAZAREVIC J.** (SER), City Hospital Valjevo, jordanlazarevic@yahoo.com –  
**P19, P57**

**LIPSKA L.** (CZ), 1st Faculty of Medicine of Charles University and Thomayer  
University Hospital, ludmila.lipska@ftn.cz – **P20, P58, P76**

**MALIKHOV A.** (RUS), Russian Cancer Research Center, Moscow,  
malikhoff@mail.ru – **P21**

**MAMMADLI Z.Z.** (RUS), Russian Cancer Research Center, Moscow,  
z.z.mamedli@gmail.com – **P22, P23**

**MARKOVIC S.** (SER), Zvezdara University Clinical Center, Belgrade,  
srdjanmarkovic@yahoo.com – **P24**

**MASLYANKOV S.** (BUL), Specialized Oncology Hospital, Veliko Tarnovo,  
ivanovatakahta@gmail.com – **P25**

**MATASOV S.** (LAT), Teko Plus Medika Ltd., Riga, matasov@hotmail.com –  
**P59**



**MILICEVIC Z.** (SER), Laboratory of Molecular Biology and Endocrinology  
Institute of Nuclear Sciences "Vinca", zorkmil@vinca.rs – **P77**

**MURATORE A.** (I), Istituto per la Ricerca e la Cura del Cancro, Torino,  
andrea.muratore@ircc.it – **P26**

**OPILKA M.N.** (POL), Silesian Medical University in Katowice,  
mieszko.opilka@googlemail.com – **P79, P80, P81**

**PARTYKA R.** (POL), St Barbara Memorial Hospital, Sosnowiec,  
robertpartyka@op.pl – **P82**

**PATY P.** (US), Memorial Sloan-Kettering Cancer Center, New York,  
patyp@mskcc.org – **P83**

**PEDOWSKI T.** (POL), Medical University in Lublin,  
tomaszpedowski@gmail.com – **P27, P28**

**PERDAWID S.K.** (DEN), Naestved Hospital, sharaf73@hotmail.com – **P60**

**PIERZCHALSKI P.** (POL), Jagiellonian University Collegium Medicum,  
Krakow, ppierzchalski@poczta.fm – **P84**

**PIKUNOV D.** (RUS), The State Research Center of Coloproctology,  
Moscow, d\_pikunov@yahoo.com – **P29**

**PORTALE G.** (I), Cittadella, Padova, giuseppe.portale@med.usc.edu – **P61, P62**

**PROCHOTSKY A.** (SLO), Hospital of Commenius University, Bratislava,  
prochotsky@pe.unb.sk – **P63**

**RAWLINSON A.** (UK), Northampton General Hospital,  
aprawlinson2003@yahoo.co.uk – **P05**

**RESTAINO G.** (I), Catholic University of Sacred Heart, Campobasso,  
gennares@hotmail.com – **P06**

**RISS S.** (A), Medical University of Vienna, Stefan.riss@meduniwien.ac.at – **P30**

**SAKAKUSHEV B.** (BUL), University Hospital St. Gerogre Plovdiv,  
bsakakushev@abv.bg – **P64, P65**

**SALAH A.** (ALG), Chu Bab El Oued, Algier,  
salahahmedcamelia@hotmail.com – **P66**

**SELVAGGI F.** (I), Second University of Naples, fselvaggi@hotmail.com – **P31**

**SLAVCHEV M.** (BUL), Military Medical Academy, Plovdiv,  
mihail\_slavchev@yahoo.com – **P67**



**SOKOLOV M.** (BUL), Medical University of Sofia, m69sokolov@abv.bg – P32, P68

**STANOJEVIC G.** (SER), Clinic for General Surgery Clinical Centre Nis, stgoran@medfak.ni.ac.rs – P69

**STARLINGER P.** (A), Medical University of Vienna, patrick.starlinger@meduniwien.ac.at – P70

**SUH K. W.** (KOR), Ajou University Hospital, Suwon, suhkw@ajou.ac.kr – P33, P34

**TAMRAZOV R. I.** (RUS), Russian Cancer Research Center, Moscow, oncopro@gmail.com – P35

**TONEV A.** (BUL), University Hospital "St. Marina", Varna, teraton@abv.bg – P42

**URYSZEK M.** (POL), Orłowski's W. Hospital, Warsaw, mariusz\_ury@mac.com – P71

**ZEGARAC M.** (SER), Institute for Oncology and Radiology in Belgrade, milan\_zegarac@yahoo.com – P43, P44



**The geographic magnitude of Central Eastern Europe is impressive.** But what good is size without proximity to the people? We view CEE as more than an investment sector – it is our home. Our subsidiaries are firmly anchored in the regions. We know the people and their traditions. We are equally as familiar with their mentality as we are with their culture. It is in this direct contact to local customers and companies that our true greatness lies.



## Firsthand information:

Erste Group operates across  
an area of 1.3 million km<sup>2</sup>.

This corresponds to almost one  
third of the entire European Union.

# SOCIAL PROGRAMME

## WELCOME RECEPTION AT THE UPPER BELVEDERE

Thursday, April 28, 19:00

Venue: Upper Belvedere  
Prinz Eugen-Str. 27, 1030 Vienna

Bus transfer from the congress: 18:30



© Belvedere, Wien



© Margherita Spiluttini

The **Welcome Reception** will take place at the Upper Belvedere. You will be served drinks and canapés in the magnificent atmosphere of the Marble Hall, followed by a guided visit of the highlights of the museum’s art collection: Gustav Klimt’s masterpieces “The Kiss” and “Judith I”.

### The Belvedere

The Belvedere’s two magnificent palaces, the Upper and Lower Belvedere, were built in the 18th century as summer residence for the important general Prince Eugene of Savoy (1663–1736) by one of the most outstanding Baroque architects, Johann Lukas von Hildebrandt (1668–1745). The palaces with their extensive gardens are considered to be one of the world’s finest Baroque landmarks.



© Belvedere, Wien

The Upper Belvedere houses an impressive collection of Austrian art, dating from the Middle Age to the present day. The heart of the displays of “art around 1900” are masterpieces by Gustav Klimt, Schiele and Kokoschka. The glittering highlights of the exposition are Klimt’s golden pictures “The Kiss” and “Judith I”. Prominent works by the French Impressionists and an outstanding collection of Viennese Biedermeier paintings are further attractions at the Upper Belvedere.

The attendance is free of charge for registered participants and accompanying persons. Please confirm your attendance when registering for the congress!



## GALA DINNER AT THE VIENNA CITY HALL

Friday, April 29, 19:30

Venue: Vienna City Hall  
Lichtenfelsgasse 2, 1010 Vienna

Individual arrival, no transfer



The Mayor and Governor of the city and province of Vienna, Dr. Michael Häupl, is pleased to invite you to the **EFR Gala Dinner** at the Vienna City Hall. We hope that you will join us for a special evening in Viennese atmosphere at the impressive Festive Hall of the Vienna City Hall.

### Background music: the Vienna Big Band Project (VBBP)



The conductor **Anton Stift** is not only an excellent colorectal surgeon but also a gifted musician. The musical repertoire of the Viennese big band stretches from Jazz and Swing to Latin and Funk and will contribute to create a lively and festive ambiance for this evening!

### Vienna City Hall

The City Hall is one of the most splendid buildings amongst the numerous monuments along Vienna's Ringstrasse. Built in a neo-Gothic style by Friedrich von Schmidt between 1872 and 1883, the 100-meter-tall edifice is the most important secular work of its style in the city. Today the City Hall is the head office of Vienna's municipal administration. More than 2000 people work in the building.



© WienTourismus/F3

The attendance is free of charge for registered participants and accompanying persons. Please confirm your attendance when registering for the congress!



## GENERAL INFORMATION

### ACCREDITATION



#### EACCME – Continuing Medical Education

The 7th International EFR Congress in Vienna will seek accreditation from the European Accreditation Council for Continuing Medical Education (EACCME). A request for accreditation has already been submitted – number of points pending. The EACCME is an institution of the European Union of Medical specialists (UEMS). ECMEC credits are recognised Europe wide and in North America. ECMEC credits can be exchanged for their national equivalent by contacting the respective National CME authority. ECMEC credits are recognised by the American Medical Association (AMA) towards the Physician's recognition Award (PRA).

#### DFP points provided by the Austrian Medical Chamber



The 7th International EFR Congress in Vienna has been accredited with 17 DFP-Points from the Austrian Medical Chamber.

### CERTIFICATE OF ATTENDANCE

Upon arrival all registered delegates will receive a certificate of attendance together with their delegates' bag.



## CONGRESS ORGANISATION

### Congress organizing committee

Teleky B., bela.teleky@meduniwien.ac.at  
Irene Kühner, irene.kuehrer@meduniwien.ac.at

Cosentini E.P.                      Judith Karner-Hanusch  
Herbst F.                             Riegler F.M.  
Daniela Kandioler                Stift A.

### Congress secretariat, exhibition & sponsoring:

#### vereint – Association- & Conference Management Ltd

Michaela Nagl  
Hollandstrasse 14  
1020 Vienna, Austria  
Tel: +43-(0)1-533 35 42-28  
Fax: +43-(0)1-219 91 80-29  
E-Mail: m.nagl@vereint.com



### Registration and housing:

#### Kuoni Destination Management Austria GmbH

Lerchenfelder Gürtel 43  
1160 Vienna, Austria  
Tel: +43-(0)1-319 76 90 - 57  
Fax: +43-(0)1-319 11 80  
E-Mail: efr2011@at.kuoni.com



## CONGRESS VENUE

### Vienna General Hospital (AKH)

Hörsaalzentrum

Address: Währinger Gürtel 18–20  
1090 Vienna, Austria

Onsite-Registration, lectures and the industry exhibition are at the „Hörsaalzentrum“. Please follow the sign posting from the main entrance of the General Hospital.

General Information



**How to get there:**

**By car:** The basement garage of the Vienna General Hospital provides 800 car parking spaces available for visitors. Entrance: Währinger Gürtel

**By taxi:** Taxis are located both in front of the main entrance and at the entrance at Lazarettgasse.

**By public transportation:**

**Underground:** Direct access to the main entrance with the underground line U6, station "Michelbeuern – AKH"

**Tram:** Line 5 and 33 (Station Lazarettgasse, entrance Spitalgasse)



**HOTEL ACCOMMODATION**

A number of hotels offering a special congress rate have been selected. For more information on the different hotels, please visit the congress website at [www.efrcancer.org](http://www.efrcancer.org). Reservations can be made online when registering for the congress. In case of questions please contact us either by phone at +43 1 319 76 90-57 or send your request to [efr2011@at.kuoni.com](mailto:efr2011@at.kuoni.com)

General Information

## LANGUAGE

The official congress language is English.  
No simultaneous translation is provided.

## REGISTRATION

### ONLINE REGISTRATION ONLY!

To register for the 7th International EFR Congress, please use our online registration system at [www.efrcongress.org](http://www.efrcongress.org)

### Registration desk & EFR congress office

The EFR congress office as well as the registration desk at the Vienna General Hospital will be open as follows:

Thursday	28.04.	12:00 – 18:00
Friday	29.04.	08:00 – 18:00
Saturday	30.04.	08:00 – 12:30

### Registration fees

	Online registration	Onsite registration
EFR member	€ 195,00	€ 255,00
Non-member	€ 290,00	€ 355,00
Resident	€ 80,00	€ 80,00
AMIC/BÖC member	€ 260,00	€ 310,00
CECS 2011 participant	€ 120,00	€ 150,00



### Delegate registration fees include:

- Access to all scientific sessions
- Access to poster exhibition
- Access to industry exhibition
- Free copy of all congress documentation
- Certificate of attendance
- Free copy of congress abstract book
- Invitation to the welcome reception – Thursday, April 28
- Invitation to the gala dinner – Friday, April 29

**Accompanying persons** are invited to the welcome reception and the gala dinner. Participation is free of charge but pre-registration for the social functions is required.

### SPEAKER INFORMATION

Speakers shall submit their \*.ppt presentation and all additional data (e.g. embedded video files, extra fonts, graphs, pictures, etc.) to the technician's desk on a CD-Rom and/or USB stick at least 1 hour prior to the session. The use of personal laptops is not allowed.

Speakers and chairs are asked to arrive 10 min before the start of their session/talk in order to guarantee a smooth event and avoid delays.



## SPONSORS & EXHIBITORS

### MAIN SPONSORS



Sponsors & Exhibitors



## FURTHER SPONSORS & EXHIBITORS



Wenckheim Holding AG



Sponsors & Exhibitors



## IMPRINT

### Publisher

European Federation for coloRectal Cancer (EFR)

Hohe Warte 56, 1190 Vienna, Austria

Tel: +43-1-378 0672

E-mail: [headoffice@efrcancer.org](mailto:headoffice@efrcancer.org); URL: [www.efrcancer.org](http://www.efrcancer.org)



### Content

No responsibility is taken for the correctness of this information. Information as per date of printing 28 February, 2011

### Layout and Design

Grafikstudio Sacher

Hietzinger Hauptstrasse 99/7, 1130 Vienna, Austria

Tel: +43-1-997 16 92, Fax: +43-1-997 16 92-10

E-mail: [office@grafikstudio-sacher.at](mailto:office@grafikstudio-sacher.at); URL: [www.grafikstudio-sacher.at](http://www.grafikstudio-sacher.at)



### Printing

Koller&Kunesch GmbH

Bahnhofstrasse 4, 5112 Lamprechtshausen, Austria

Phone: +43-(0)6274-429710 | Fax: +43(0)6274-42976

E-mail: [office@koller-kunesch.at](mailto:office@koller-kunesch.at); URL: [www.koller-kunesch.at](http://www.koller-kunesch.at)





Notes



# „Beratung schafft Transparenz.“



Damit Sie in jeder Situation den Blick auf das Wesentliche nicht verlieren. Wenn es um Transparenz und Klarheit geht, drehen wir an jedem noch so kleinen Rädchen. So bleiben Ihre Finanzen für Sie immer greifbar.



**Raiffeisen Private Banking.**

**Leistung garantiert.**

Über das Private Banking-

Leistungsversprechen informieren

Sie gerne unsere FinanzBerater.

Besuchen Sie uns auf:

[www.privatebanking-raiffeisen.at](http://www.privatebanking-raiffeisen.at)

**Raiffeisen in Wien**  
Private Banking



[ The power is in your hand. ]

## Precision. Control. Access.

The iDrive™ powered handle and Right Angle Linear Cutter (RALC). This innovative, reusable stapling platform offers microprocessor-controlled precision and push button control along with deeper access to and better visibility in the pelvis<sup>1</sup> for low anterior resection procedures.



**To learn more visit the Covidien booth at the EFR Congress of the European Federation for Colorectal Cancer in Vienna, Austria.**

<sup>1</sup>When compared to the EES Contour™\*, the iDrive™ powered handle and RALC could be placed deeper and provided better visibility in the low pelvis in male cadavers; data on file. COVIDIEN, COVIDIEN with logo, Covidien logo and "positive results for life" or other brands are internationally registered trademarks of Covidien AG, or a Covidien company. © 2010 Covidien



**COVIDIEN**

*positive results for life™*